Study of Adrenal Gland Tumors
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00005927|
Recruitment Status : Completed
First Posted : June 29, 2000
Last Update Posted : September 7, 2020
The adrenal glands, located atop the kidneys, normally produce several types of hormones. Tumors of these glands may or may not secrete hormones. It is not known what causes these tumors or why some secrete hormones and others do not. Some of the tumors are benign and confined to the adrenal gland, and others are malignant (cancerous), and can spread to other parts of the body. This study will investigate how adrenal gland tumors develop, why some secrete steroid hormones and others do not, and why some are benign and others malignant.
Patients between 3 and 70 years old with a known or suspected adrenal gland tumor may be eligible for this study. Participants will be hospitalized for 7 to 10 days for various tests and procedures that may include the following:
- Medical history and physical examination, including body measurements, as appropriate. Children and adolescents will have Tanner staging, including examination of the genitals, to determine the extent of sexual maturity.
- 24-hour urine collection to measure hormones in the urine.
- Imaging studies, including magnetic resonance imaging (MRI) of the brain, computed tomography (CT) and other X-ray studies.
- Blood tests to see if the tumor secretes hormones in response to specific stimuli, including exercise, food, and various hormones. The hormones are given through an intravenous catheter, or IV a thin plastic tube inserted into an arm vein. After the stimulus, blood is drawn through the same IV every 30 minutes for up to 3 hours to measure hormone levels. Based on the results of these tests, some patients may have additional blood tests to check hormone response to special foods, an IV salt solution, or other hormones or drugs given either IV or by mouth (in pill form).
- Photographs to document the effects on the body of abnormal hormone secretion from the adrenal tumor.
- Small samples of blood and tumor tissue for research and DNA (genetic) analysis.
A discussion of treatment options will be based on the results of tests. If surgery to remove the tumor is recommended, the procedure can be done at NIH under this study protocol. If a malignant tumor is found that cannot be treated surgically, chemotherapy or radiation therapy may be recommended. These options are not offered under this protocol, but may be available under a different NIH study (for example, at the National Cancer Institute). Referrals will be made at the patient s request.
Patients who had surgery may be followed at the NIH outpatient clinic for 1 year after surgery. Patients with certain types of tumors may continue to be followed at NIH once a year for up to 5 years.
A registry of study participants will be created to keep records and correlate medical histories with tissues kept at NIH. The registry will also be used to inform participants of research studies they may be interested in. No individuals or organizations outside of NIH will have access to the registry.
|Condition or disease|
|Adrenal Gland Neoplasm|
|Study Type :||Observational|
|Actual Enrollment :||690 participants|
|Official Title:||Clinical and Molecular Analysis of ACTH-Independent Steroid Hormone Production in Adrenocortical Tissue|
|Actual Study Start Date :||July 1, 2002|
Hyperaldosteronism and cushing participants
Subjects with Hyperaldosteronism and cushing. Adults, pediatric subjects and family members (DNA collection only for family members).
- To study the contribution of ectopic/abnormal membrane hormone receptor expression in the adrenal gland to the pathogenesis of primary adrenocortical hormone over-secretion syndromes [ Time Frame: This is an ongoing project ]-to define the germline and/or somatic genetic mutations causing ACTH-independent ushing s syndrome; -to define the biochemicalfunctionality of mutations in adrenocortical tumor; -to investigate novel therapeutic strategies to control hormone oversecretion of biochemically active adrenal tumors
- To investigate the renal, cardiac, metabolic, and bone effects of hyperaldosteronism. To utilize high-density gene array analysis to identify patterns of gene expression that will discriminate between benign and malignant adrenal tumors. [ Time Frame: This is an ongoing project ]-to investigate co-secretion of other steroids; -to investigate cardiac, renal, metabolic and coagulopathic consequences of primary aldosteronism; -to investigate the clinical utility of other biomarkers in classifying adrenal disorders
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00005927
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||Constantine A Stratakis, M.D.||Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|